Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review.

Josep M LlibrePedro E CahnJanet LoTristan J BarberCristina MussiniBerend J van WelzenBeatriz HernandezCynthia DonovanMichelle KisareMyooran SithamparanathanJean van Wyk

Published in: Open forum infectious diseases (2022)

Results show that dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis biomarkers vs 3/4DRs, with no consistent pattern of change after switch in virologically suppressed PWH.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
oxidative stress
hepatitis c virus
drug induced